Quality of Life of Postmenopausal Women in the ATAC (“Arimidex”, Tamoxifen, Alone or in Combination) Trial after Completion of 5 years' Adjuvant Treatment for Early Breast Cancer

By Cella David   Fallowfield Lesley   Barker Peter   Cuzick Jack   Locker Gershon   Howell Anthony  

Breast Cancer Research and Treatment, Vol. 100, Iss. 3, 2006-12 ,pp. : 273-284

Springer Publishing Company

Access to resources Recommend Favorite

Adjuvant Tamoxifen: The Risks Versus the Benefits of Long-Term Therapy

By Schlesinger K.W.   Vogel V.G.  

American Journal of Cancer, Vol. 1, Iss. 6, 2002-01 ,pp. : 375-386

Adis International

Access to resources Recommend Favorite

Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2–3 years treatment with tamoxifen in Sweden

By Lundkvist Jonas   Wilking Nils   Holmberg Stig   Jönsson Linus  

Breast Cancer Research and Treatment, Vol. 102, Iss. 3, 2007-05 ,pp. : 289-299

Springer Publishing Company

Access to resources Recommend Favorite

Postoperative Adjuvant Randomised Trial Comparing Chemoendocrine Therapy, Chemotherapy and Immunotherapy for Patients with Stage II Breast Cancer: 5-year Results from The Nishinihon Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer (ACETBC) of Japan

By Morimoto T.   Ogawa M.   Orita K.   Sugimachi K.   Toge T.   Dohi K.   Nomura Y.   Monden Y.   Ogawa N.  

European Journal of Cancer, Vol. 32, Iss. 2, 1996-02 ,pp. : 235-242

Elsevier

Access to resources Recommend Favorite

Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: Cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial

By Purmonen Timo T.   Päänkäälääinen Emma   Turunen Juha H. O.   Asseburg Christian   Martikainen Janne A.  

Acta Oncologica, Vol. 50, Iss. 3, 2011-04 ,pp. : 344-352

Informa Healthcare

Access to resources Recommend Favorite